Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.

Inclusion Criteria: * Healthy adults aged 18-60yrs, with BMI of 19-31kg/m2. * Females must be of non-childbearing potential. * Subjects must be able to give consent and comply with restrictions of study. Exclusion Criteria: * Clinically relevant abnormality from history, physical, 12-lead ECG, Holter monitoring, or clinical laboratory examination. * Positive urine drug screen. * Positive urine test for alcohol. * Contine levels indicative of smoking. * Positive HIV or Hep B and/or C assay. * History or smoking in last year or \>10 pack/year history of smoking overall. * History of regular alcohol consumption (7 units/week for women and 14 units/week for men) within 6 months of study. * History of drug abuse within 6 months of study. * Participation in another drug trial within 30 days of first dose. * Exposure to more than 4 new chemical entities within 12 months of first dose. * Use of prescription and non-prescription drugs including dietary supplements, herbals and St. John's wort within 14 days of first dose. * Consumption of red wine, grapefruit, grapefruit juice and grapefruit products within 14 days of first dose. * Donation of blood in excess of 500 mL within 56 days of dosing. * Evidence of renal, hepatic or biliary impairment. * History of serious gastrointestinal disease or history of gastrointestinal surgical procedure that might affect absorption of study drug. * History of sensitivity to any of the study medications. * History of clinically significant cardiovascular disease. * History of pernicious anemia, pancreatitis, osteosarcoma or kidney stones. Medical conditions which might alter bone metabolism. * Liver function tests above ULN at screening and PTH, glucose, and CPK outside the reference range at screening. * Males unwilling to refrain from fathering a child during the study and for 14 days following the last dose of study medication.